Melanotan-2 is a synthetic cyclic heptapeptide that functions as a non-selective melanocortin-receptor agonist, modeled on the endogenous hormone α-melanocyte-stimulating hormone (α-MSH). As an α-MSH analogue, Melanotan-2 (also written Melanotan II or MT-2) binds and activates multiple receptors in the melanocortin family, which has made it a recurring tool compound for laboratories studying melanocortin signalling and pigmentation biology in cell and animal models. This guide explains what Melanotan-2 is at the molecular level, which receptors it engages, what published research has characterised about its mechanism, and how laboratories handle and verify the material — strictly for research use only.
To understand Melanotan-2, start with the hormone it imitates. α-Melanocyte-stimulating hormone (α-MSH) is one of the melanocortins — a group of peptide hormones cleaved from the precursor protein pro-opiomelanocortin (POMC). The melanocortins share a common core sequence (His-Phe-Arg-Trp) that is essential for binding the melanocortin receptors. Native α-MSH is a short linear peptide, and like many natural peptides it is rapidly degraded by enzymes, giving it a brief half-life. That instability is precisely the problem medicinal-chemistry researchers set out to address when they designed analogues in the 1980s.
Melanotan-2 is the result of one such design effort. It is a cyclic heptapeptide — seven amino acids closed into a ring through a lactam bridge — that preserves the critical melanocortin pharmacophore while resisting enzymatic breakdown far better than the linear parent hormone. The cyclisation and amino-acid substitutions give the molecule greater metabolic stability and receptor potency in research assays compared with native α-MSH. In short, Melanotan-2 is a superpotent, structurally stabilised α-MSH analogue built so that researchers can probe melanocortin signalling with a more durable ligand.
Because it retains the shared melanocortin core rather than a subtype-selective motif, Melanotan-2 binds broadly across the melanocortin receptor family. This non-selectivity is a defining pharmacological feature and the reason it is described as a non-selective melanocortin-receptor agonist rather than, say, a dedicated MC1R agonist.
Melanotan-2 is frequently confused with Melanotan-1, and the two are genuinely related but not interchangeable. Melanotan-1 — known by the research/pharmaceutical name afamelanotide — is a linear α-MSH analogue, also designed for stability, but with a different structure and a different receptor-selectivity profile. Melanotan-2, by contrast, is cyclic and engages a broader range of melanocortin receptors. The practical upshot for researchers is that the two compounds are not pharmacological substitutes: their structures, potencies, and receptor-engagement patterns differ, and studies that characterise one cannot be assumed to apply to the other. When the literature refers simply to "Melanotan," context is required to know which analogue is meant.
Melanotan-2's behaviour only makes sense against the backdrop of the melanocortin receptor (MCR) system. The melanocortin receptors are a family of five G-protein-coupled receptors (GPCRs), designated MC1R through MC5R, each with a distinct tissue distribution and physiological role. All five couple primarily to the stimulatory G-protein Gs, meaning that agonist binding typically raises intracellular cyclic AMP (cAMP) — the second messenger that propagates the signal inside the cell.
A brief orientation to the family clarifies which receptors matter for Melanotan-2 research:
Because Melanotan-2 is non-selective, it can engage MC1R, MC3R, MC4R, and MC5R as an agonist (MC2R being the outlier that prefers ACTH). In practice, the research literature concentrates on its MC1R activity in pigment-cell models and its MC3R/MC4R activity in central-melanocortin models. This breadth is exactly why Melanotan-2 is useful as a pan-melanocortin probe — and also why interpreting its effects requires care, since multiple receptor systems can be engaged at once.
The mechanistic literature on Melanotan-2 is best understood receptor by receptor, because the molecule's non-selectivity means it activates several parallel signalling routes.
The most thoroughly characterised mechanism is at MC1R on melanocytes. When an agonist such as Melanotan-2 binds MC1R, the receptor couples through Gs to activate adenylyl cyclase, raising intracellular cAMP. Elevated cAMP activates protein kinase A (PKA), which phosphorylates the transcription factor CREB (cAMP-response-element-binding protein). CREB in turn upregulates MITF (microphthalmia-associated transcription factor), the master regulator of the melanogenesis gene program.
MITF drives expression of the enzymes that build melanin — most importantly tyrosinase, the rate-limiting enzyme in pigment synthesis, along with TRP-1 and TRP-2 (DCT). The downstream consequence in pigment-cell research is a shift in melanin production, including a shift toward eumelanin synthesis. This MC1R → cAMP → PKA → CREB → MITF → tyrosinase cascade is the canonical pigmentation-signalling axis, and Melanotan-2 is a frequently used agonist tool for activating it in cultured melanocytes and melanoma cell lines studied in pigmentation biology. To be explicit: this is a description of a cell-signalling pathway studied in research models, not a description of any effect intended for, or applicable to, people.
Away from the skin, the central melanocortin system — built largely around MC3R and MC4R in the brain — is one of the most studied signalling networks in metabolic and neurological research. Because Melanotan-2 is a non-selective agonist, it also activates these central receptors, again principally through Gs/cAMP coupling. For this reason, Melanotan-2 has been employed in animal-model research as a melanocortin-pathway agonist to interrogate MC3R/MC4R signalling and the broader physiology of the central melanocortin circuitry.
It is important to frame this accurately: the relevance of MC3R/MC4R activation here is mechanistic and confined to research models. These receptors are studied because the melanocortin system is biologically central, and Melanotan-2 serves as a pharmacological tool to probe it — nothing in this section describes or endorses any use in humans.
The throughline across these mechanisms is non-selectivity. Unlike a designed subtype-selective ligand, Melanotan-2 activates multiple melanocortin receptors in parallel. In experimental terms this is a feature — it makes the compound a broad probe of melanocortin biology — but it also means that any observed effect in a complex system may reflect convergent signalling across several receptors, which researchers must account for in study design and interpretation.
The mechanisms above translate into a small number of well-defined research areas. The correct framing throughout is that researchers have investigated these topics in laboratory systems — Melanotan-2 is a tool compound, not an approved or directed product for any human or animal use.
The first and broadest area is the melanocortin pathway itself. Because Melanotan-2 is a stable, potent, non-selective agonist, it is valuable for interrogating melanocortin-receptor pharmacology — characterising receptor binding, cAMP signalling output, agonist potency, and the comparative behaviour of the receptor subtypes. In this context the compound is essentially a research reagent for melanocortin GPCR studies, used to map how the system responds to agonist stimulation in vitro.
The second major area is pigmentation biology. In cultured melanocytes, melanoma cell lines, and animal models, Melanotan-2 has been used to activate the MC1R/MITF/tyrosinase axis and to study the regulation of melanogenesis at the molecular level — how pigment-synthesis genes are switched on, how the eumelanin/pheomelanin balance is controlled, and how melanocyte signalling integrates upstream cues. This research lineage explains why Melanotan-2 appears so often in the pigment-cell literature, purely as a laboratory tool for dissecting the biology of melanin production in model systems.
The third area is central melanocortin physiology in animal models, where the compound's MC3R/MC4R agonism is used to probe the brain's melanocortin circuitry. This sits within a large neuroscience and physiology literature on the melanocortin system, and Melanotan-2's role there is as a pan-agonist tool for activating central receptors in experimental preparations.
Across all three areas the boundary is the same: these are mechanistic and model-system investigations. Describing them is not a statement that the compound produces any benefit, effect, or outcome in humans, and this article makes no such claim.
The following describes general laboratory handling practice for lyophilised research peptides such as Melanotan-2. It is provided as laboratory context only and is not guidance for any use in humans or animals.
Research-grade Melanotan-2 is typically supplied as a lyophilised (freeze-dried) powder, a form chosen because dry peptide is far more stable than peptide in solution. In a laboratory setting, the powder is generally reconstituted with an appropriate solvent — commonly bacteriostatic or sterile water for laboratory preparations — added slowly down the side of the vial rather than directly onto the powder, then dissolved by gentle swirling rather than vigorous shaking, which can shear and degrade the peptide.
For storage, the standard conventions for lyophilised peptides apply:
These are compound-integrity conventions for preserving material for experiments — nothing here implies preparation for consumption.
For research use, analytical quality is the entire value proposition — experimental results are only as trustworthy as the material that produced them. Two pillars define reputable research-grade Melanotan-2.
First, HPLC purity. High-performance liquid chromatography (HPLC) separates a sample into its components and quantifies the target peptide relative to impurities, yielding a stated purity percentage (high purity is the expected standard for research peptides). For a cyclic peptide like Melanotan-2, HPLC is typically paired with mass spectrometry (MS) to confirm identity — that the measured molecular mass matches the expected structure, including correct cyclisation. Together, HPLC and MS answer the two questions that matter most: what the compound is and how pure it is.
Second, the Certificate of Analysis (COA). A COA is the batch-specific document that reports a given lot's analytical results — identity, purity, and the methods used to determine them. A credible supplier provides a per-batch COA rather than a generic claim, so the exact material in hand can be traced to its own test data. For any serious research program the principle is simple: no COA, no confidence. The certificate is what distinguishes a characterised research compound from an unknown powder.
| Property | Detail |
|---|---|
| Compound names | Melanotan-2, Melanotan II, MT-2 |
| Classification | Synthetic cyclic peptide; non-selective melanocortin-receptor agonist — research use only |
| Parent hormone | Analogue of α-melanocyte-stimulating hormone (α-MSH), a melanocortin derived from POMC |
| Peptide class | Cyclic heptapeptide (lactam-bridged; metabolically stabilised vs native α-MSH) |
| Receptor targets | Agonist at MC1R, MC3R, MC4R (and MC5R); MC2R prefers ACTH |
| Primary signalling | Gs → adenylyl cyclase → cAMP → PKA → CREB → MITF → tyrosinase (MC1R/melanogenesis axis) |
| Related compound | Melanotan-1 (afamelanotide) — a linear α-MSH analogue with different selectivity |
| Physical form | Lyophilised (freeze-dried) powder |
| Lab storage | Cold, dry, light-protected; refrigerate/freeze the powder; avoid freeze-thaw cycles |
| Purity standard | HPLC-verified high purity; identity confirmed by mass spectrometry |
| Documentation | Batch-specific Certificate of Analysis (COA) |
For laboratories sourcing this compound, our Melanotan II 10mg listing sits within the broader Research Peptides category, where related melanocortin and peptide research compounds are grouped together.
Melanotan-2 (Melanotan II, MT-2) is a synthetic cyclic heptapeptide designed as an analogue of the hormone α-melanocyte-stimulating hormone (α-MSH). Pharmacologically, it behaves as a non-selective melanocortin-receptor agonist, engaging several receptors in the melanocortin family. It is a research-use-only compound studied in melanocortin and pigmentation biology.
As a non-selective agonist, Melanotan-2 activates multiple melanocortin receptors — principally MC1R, MC3R, and MC4R, with activity also reported at MC5R. MC2R, the adrenal ACTH receptor, is the family outlier and is not a primary Melanotan-2 target. Research most often focuses on its MC1R activity in pigment cells and its MC3R/MC4R activity in central-melanocortin models.
At MC1R, agonist binding couples through the Gs protein to adenylyl cyclase, raising cAMP, which activates PKA, then CREB, then MITF — the master regulator that upregulates tyrosinase and the melanogenesis program. The same Gs/cAMP logic applies at the central MC3R/MC4R receptors. This describes a cell-signalling cascade in research models, not an effect in people.
Melanotan-2 is a cyclic peptide that engages a broad range of melanocortin receptors, whereas Melanotan-1 (afamelanotide) is a linear α-MSH analogue with a different structure and receptor-selectivity profile. They are related but not interchangeable, and research characterising one does not transfer directly to the other.
It should be characterised by HPLC for purity and by mass spectrometry for identity (confirming the molecular mass and correct cyclisation of the peptide). Reputable material ships with a batch-specific Certificate of Analysis (COA) documenting those results — the standard basis for trusting a research peptide.
For laboratory work, sourcing quality is non-negotiable. Research-grade Melanotan-2 from Alluvia Peptides is HPLC-verified for purity, identity-confirmed by mass spectrometry, ships with a Certificate of Analysis on every batch, and is handled with cold-chain logistics to preserve compound integrity from our facility to your bench.
Order the product directly: Melanotan II 10mg.
Or browse related research compounds in the Research Peptides category.
Research use only — not for human consumption. All information in this article is provided for educational and research purposes only. Melanotan-2 and related peptides discussed here are intended exclusively for in-vitro laboratory research and development use. They are not drugs, supplements, cosmetics, or food, are not approved for human or animal use, and are not intended to diagnose, treat, cure, or prevent any disease. Nothing in this article constitutes medical advice or instructions for human or animal use, and nothing here describes how the compound is used in or on people.